Please use this identifier to cite or link to this item:
http://hdl.handle.net/1942/30883
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | VAN WIJMEERSCH, Bart | - |
dc.contributor.author | Singer, Barry A. | - |
dc.contributor.author | Boster, Aaron | - |
dc.contributor.author | Broadley, Simon | - |
dc.contributor.author | Fernandez, Oscar | - |
dc.contributor.author | Freedman, Mark S. | - |
dc.contributor.author | Izquierdo, Guillermo | - |
dc.contributor.author | Lycke, Jan | - |
dc.contributor.author | Pozzilli, Carlo | - |
dc.contributor.author | Sharrack, Basil | - |
dc.contributor.author | Steingo, Brian | - |
dc.contributor.author | Wiendl, Heinz | - |
dc.contributor.author | Wray, Sibyl | - |
dc.contributor.author | Ziemssen, Tjalf | - |
dc.contributor.author | Chung, Luke | - |
dc.contributor.author | Margolin, David H. | - |
dc.contributor.author | Thangavelu, Karthinathan | - |
dc.contributor.author | Vermersch, Patrick | - |
dc.date.accessioned | 2020-03-30T08:10:22Z | - |
dc.date.available | 2020-03-30T08:10:22Z | - |
dc.date.issued | 2020 | - |
dc.date.submitted | 2020-01-28T14:39:36Z | - |
dc.identifier.citation | MULTIPLE SCLEROSIS JOURNAL, 26 (13), p. 1719-1728 | - |
dc.identifier.issn | 1352-4585 | - |
dc.identifier.uri | http://hdl.handle.net/1942/30883 | - |
dc.description.abstract | Background:Alemtuzumab is administered as two annual courses for relapsing-remitting multiple sclerosis (MS). Patients may relapse before completing the two-course regimen. Objective: The objective was to evaluate 6-year outcomes in patients who relapsed between alemtuzumab Courses 1 and 2 (early relapsers). Methods:Post hoc analysis of patients from the Comparison of Alemtuzumab and Rebif (R) Efficacy in Multiple Sclerosis (CARE-MS) studies who enrolled in the extension. Results:Early relapsers (CARE-MS I: 15%; CARE-MS II: 24%) had more relapses in 1-2 years pre-alemtuzumab and higher mean baseline Expanded Disability Status Scale score than patients without relapse. Their annualized relapse rate declined from Year 1 (CARE-MS I: 1.3; CARE-MS II: 1.2) to Year 2 following Course 2 (0.3; 0.5) and remained low thereafter. Over 6 years, 60% remained free of 6-month confirmed disability worsening; 24% (CARE-MS I) and 34% (CARE-MS II) achieved 6-month confirmed disability improvement. During Year 6, 69% (CARE-MS I) and 68% (CARE-MS II) were free of magnetic resonance imaging (MRI) disease activity. Median percent yearly brain volume loss (Year 1: -0.67% (CARE-MS I); -0.47% (CARE-MS II)) declined after Course 2 (Year 6: -0.24%; -0.13%). Conclusion: Early relapsers' outcomes improved after completing the second alemtuzumab course. These findings support administering the approved two-course regimen to maximize clinical benefit. ClinicalTrials.gov registration numbers:CARE-MS I, II, extension: NCT00530348, NCT00548405, NCT00930553. | - |
dc.description.sponsorship | The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: The CARE-MS I, CARE-MS II, and CAMMS03409 studies were funded by Sanofi and Bayer HealthCare Pharmaceuticals. Only Sanofi contributed to the conduct of the studies; collection, management, analysis, and interpretation of the data; review of the manuscript. Apart from the Sanofi employees listed as authors, the funders had no role in preparation, approval, and decision to submit the manuscript for publication. | - |
dc.language.iso | en | - |
dc.publisher | SAGE PUBLICATIONS LTD | - |
dc.rights | The Author(s), 2019. ( CC-BY-NC )Article reuse guidelines: sagepub.com/journalspermissions | - |
dc.subject.other | Alemtuzumab | - |
dc.subject.other | disease-modifying therapy | - |
dc.subject.other | relapsing-remitting multiple sclerosis (MS) | - |
dc.subject.other | efficacy | - |
dc.subject.other | magnetic resonance imaging (MRI) | - |
dc.subject.other | disability | - |
dc.title | Efficacy of alemtuzumab over 6 years in relapsing–remitting multiple sclerosis patients who relapsed between courses 1 and 2: Post hoc analysis of the CARE-MS studies | - |
dc.type | Journal Contribution | - |
dc.identifier.epage | 1728 | - |
dc.identifier.issue | 13 | - |
dc.identifier.spage | 1719 | - |
dc.identifier.volume | 26 | - |
local.format.pages | 10 | - |
local.bibliographicCitation.jcat | A1 | - |
dc.description.notes | Van Wijmeersch, B (reprint author), Hasselt Univ, Fac Med & Life Sci, Campus Hasselt,Martelarenlaan 42, B-3500 Hasselt, Belgium. | - |
dc.description.notes | bart.vanwijmeersch@uhasselt.be | - |
dc.description.other | Van Wijmeersch, B (reprint author), Hasselt Univ, Fac Med & Life Sci, Campus Hasselt,Martelarenlaan 42, B-3500 Hasselt, Belgium. bart.vanwijmeersch@uhasselt.be | - |
local.publisher.place | 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND | - |
local.type.refereed | Refereed | - |
local.type.specified | Article | - |
dc.source.type | Article | - |
dc.identifier.doi | 10.1177/1352458519881759 | - |
dc.identifier.pmid | 31675266 | - |
dc.identifier.isi | WOS:000495335100001 | - |
dc.contributor.orcid | Ziemssen, Tjalf/0000-0001-8799-8202 | - |
dc.identifier.eissn | 1477-0970 | - |
local.provider.type | wosris | - |
local.uhasselt.uhpub | yes | - |
local.uhasselt.international | yes | - |
item.validation | ecoom 2020 | - |
item.accessRights | Open Access | - |
item.fullcitation | VAN WIJMEERSCH, Bart; Singer, Barry A.; Boster, Aaron; Broadley, Simon; Fernandez, Oscar; Freedman, Mark S.; Izquierdo, Guillermo; Lycke, Jan; Pozzilli, Carlo; Sharrack, Basil; Steingo, Brian; Wiendl, Heinz; Wray, Sibyl; Ziemssen, Tjalf; Chung, Luke; Margolin, David H.; Thangavelu, Karthinathan & Vermersch, Patrick (2020) Efficacy of alemtuzumab over 6 years in relapsing–remitting multiple sclerosis patients who relapsed between courses 1 and 2: Post hoc analysis of the CARE-MS studies. In: MULTIPLE SCLEROSIS JOURNAL, 26 (13), p. 1719-1728. | - |
item.fulltext | With Fulltext | - |
item.contributor | VAN WIJMEERSCH, Bart | - |
item.contributor | Singer, Barry A. | - |
item.contributor | Boster, Aaron | - |
item.contributor | Broadley, Simon | - |
item.contributor | Fernandez, Oscar | - |
item.contributor | Freedman, Mark S. | - |
item.contributor | Izquierdo, Guillermo | - |
item.contributor | Lycke, Jan | - |
item.contributor | Pozzilli, Carlo | - |
item.contributor | Sharrack, Basil | - |
item.contributor | Steingo, Brian | - |
item.contributor | Wiendl, Heinz | - |
item.contributor | Wray, Sibyl | - |
item.contributor | Ziemssen, Tjalf | - |
item.contributor | Chung, Luke | - |
item.contributor | Margolin, David H. | - |
item.contributor | Thangavelu, Karthinathan | - |
item.contributor | Vermersch, Patrick | - |
crisitem.journal.issn | 1352-4585 | - |
crisitem.journal.eissn | 1477-0970 | - |
Appears in Collections: | Research publications |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
van-wijmeersch-et-al-2019-efficacy-of-alemtuzumab-over-6-years-in-relapsing-remitting-multiple-sclerosis-patients-who.pdf | Published version | 814.73 kB | Adobe PDF | View/Open |
SCOPUSTM
Citations
3
checked on Sep 5, 2020
WEB OF SCIENCETM
Citations
13
checked on May 8, 2024
Page view(s)
32
checked on Sep 7, 2022
Download(s)
8
checked on Sep 7, 2022
Google ScholarTM
Check
Altmetric
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.